Market Research Logo

Hemophilia B - Pipeline Review, H2 2015

Hemophilia B - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Hemophilia B - Pipeline Review, H2 2015’, provides an overview of the Hemophilia B’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hemophilia B
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hemophilia B and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hemophilia B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hemophilia B pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hemophilia B
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hemophilia B pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Hemophilia B Overview
Therapeutics Development
Pipeline Products for Hemophilia B - Overview
Pipeline Products for Hemophilia B - Comparative Analysis
Hemophilia B - Therapeutics under Development by Companies
Hemophilia B - Therapeutics under Investigation by Universities/Institutes
Hemophilia B - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hemophilia B - Products under Development by Companies
Hemophilia B - Products under Investigation by Universities/Institutes
Hemophilia B - Companies Involved in Therapeutics Development
Alnylam Pharmaceuticals, Inc.
Amarna Therapeutics B.V.
AstraZeneca Plc
Baxalta Incorporated
Bayer AG
Biogen, Inc.
Catalyst Biosciences, Inc.
CSL Limited
Dimension Therapeutics, Inc.
Emergent BioSolutions Inc.
Novo Nordisk A/S
OPKO Health, Inc.
Pfizer Inc.
Pharming Group N.V.
RegenxBio Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Spark Therapeutics, Inc.
uniQure N.V.
Hemophilia B - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
albutrepenonacog alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-AT3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMT-060 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZ-10047130 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAX-335 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY-1093884 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-2679d - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-813d - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cell Therapy for Hemophilia B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
coagulation factor IX (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
coagulation factor IX (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
coagulation factor IX-Fc (recombinant), Fc fusion protein - Drug Profile
Product Description
Mechanism of Action
R&D Progress
coagulation factor VIIa (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
concizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSL-689 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DTX-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Hemophilia B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LR-769 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOD-5014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MOD-9017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nonacog beta pegol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-06741086 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-FIX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPK-FIX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SVF-VIIa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hemophilia B - Recent Pipeline Updates
Hemophilia B - Dormant Projects
Hemophilia B - Discontinued Products
Hemophilia B - Product Development Milestones
Featured News & Press Releases
Sep 17, 2015: Dimension Therapeutics Announces FDA Fast Track Designation for Lead Candidate DTX101 in Patients with Hemophilia B
Sep 10, 2015: Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Orphan Drug Designation for Lead Candidate DTX101 in Patients with Hemophilia B
Aug 17, 2015: Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B
Jul 28, 2015: Swissmedic Accepts for Review CSL Behring’s MAA for rIX-FP for Patients with Hemophilia B
Jun 26, 2015: Biogen and Sobi Announce European Medicines Agency Validates ALPROLIX (rFIXFc) Marketing Authorization Application
Jun 24, 2015: CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015
Jun 24, 2015: Baxalta Reports Continued Progress on Phase 1/2 Clinical Trial of BAX335, Investigational Gene Therapy Treatment for Hemophilia B
Jun 16, 2015: Catalyst Biosciences Announces CB 2679d Data Presentations at the 2015 International Society on Thrombosis and Haemostatsis Meeting
Jun 16, 2015: Catalyst Biosciences Announces PF-05280602 Data Presentations at the 2015 International Society on Thrombosis and Haemostatsis Meeting
Jun 04, 2015: Sobi's partner Biogen submits marketing authorisation application for Alprolix (rFIXFc) in Europe
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hemophilia B, H2 2015
Number of Products under Development for Hemophilia B - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Products under Investigation by Universities/Institutes, H2 2015
Hemophilia B - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015
Hemophilia B - Pipeline by Amarna Therapeutics B.V., H2 2015
Hemophilia B - Pipeline by AstraZeneca Plc, H2 2015
Hemophilia B - Pipeline by Baxalta Incorporated, H2 2015
Hemophilia B - Pipeline by Bayer AG, H2 2015
Hemophilia B - Pipeline by Biogen, Inc., H2 2015
Hemophilia B - Pipeline by Catalyst Biosciences, Inc., H2 2015
Hemophilia B - Pipeline by CSL Limited, H2 2015
Hemophilia B - Pipeline by Dimension Therapeutics, Inc., H2 2015
Hemophilia B - Pipeline by Emergent BioSolutions Inc., H2 2015
Hemophilia B - Pipeline by Novo Nordisk A/S, H2 2015
Hemophilia B - Pipeline by OPKO Health, Inc., H2 2015
Hemophilia B - Pipeline by Pfizer Inc., H2 2015
Hemophilia B - Pipeline by Pharming Group N.V., H2 2015
Hemophilia B - Pipeline by RegenxBio Inc., H2 2015
Hemophilia B - Pipeline by rEVO Biologics, Inc., H2 2015
Hemophilia B - Pipeline by Sangamo BioSciences, Inc., H2 2015
Hemophilia B - Pipeline by Spark Therapeutics, Inc., H2 2015
Hemophilia B - Pipeline by uniQure N.V., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hemophilia B Therapeutics - Recent Pipeline Updates, H2 2015
Hemophilia B - Dormant Projects, H2 2015
Hemophilia B - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Hemophilia B, H2 2015
Number of Products under Development for Hemophilia B - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report